Clinical Trials Logo
  1. Home
  2. Postpartum Hemorrhage
  3. NCT06164236
  4. Details
NCT06164236 Clinical Trial

Study of Predictors of Failure of Sulprostone Treatment in Postpartum Hemorrhage

Postpartum Hemorrhage Clinical Trial

— NALAPOST  

Official title:
Study of Predictors of Failure of Sulprostone Treatment in Postpartum Hemorrhage

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06164236
Other study ID # 8013
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 19, 2020
Est. completion date December 31, 2023

Study information
Verified date December 2022
Source University Hospital, Strasbourg, France
Contact Sandrine VOILLEQUIN, Midwife
Phone 33 3 69 55 34 92
Email sandrine.voillequin@chru-strasbourg.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators wish to identify potential factors predicting failure of second-line drug treatment (sulproston (Nalador®)): risk factors and factors linked to a failure to take initial care for PPH. A better understanding of the aggravating factors of HPP and more particularly the factors inherent to the initial care would make it possible to think of ways to improve practices.

Recruitment information / eligibility
Status Recruiting
Enrollment 300
Est. completion date December 31, 2023
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Major subject (=18 years old) - Subject having given birth at HUS or CHU Poissy Saint-Germain-en Laye between 01/01/2019 and 31/12/2019 - Subject having presented a postpartum haemorrhage treated with Sulprostone - Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research Exclusion Criteria: - Subject having expressed opposition to participating in the study - Subject under guardianship or guardianship - Subject under safeguard of justice

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France École de sages-femmes de Strasbourg Strasbourg Starsbourg

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Identify a potential predictors of failure of second-line drug treatment in the case of severe postpartum hemorrhage 1 year
See also
  Status Clinical Trial Phase
Completed NCT03434444 - In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol N/A
Terminated NCT01980173 - Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care N/A
Not yet recruiting NCT06033170 - Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage N/A
Not yet recruiting NCT02319707 - Management of the Third Stage of Labor Phase 3
Completed NCT02163616 - Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study Phase 3
Recruiting NCT01600612 - Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial N/A
Completed NCT02079558 - Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section Phase 2
Withdrawn NCT01108302 - Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India N/A
Completed NCT00097123 - RCT of Misoprostol for Postpartum Hemorrhage in India N/A
Completed NCT02883673 - Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage N/A
Completed NCT02542813 - Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers Phase 1
Completed NCT04201665 - EMG for Uterotonic Efficiency Estimation N/A
Terminated NCT03246919 - Ideal Time of Oxytocin Infusion During Cesarean Section Phase 4
Not yet recruiting NCT05501106 - Reducing Postpartum Hemorrhage After Vaginal Delivery N/A
Completed NCT05429580 - Prophylactic Tranexamic Acid Use After Vaginal Delivery N/A
Terminated NCT03064152 - Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery N/A
Recruiting NCT05382403 - Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage N/A
Completed NCT02910310 - Introduction of UBT for PPH Management in Three Countries N/A
Completed NCT03344302 - Oxytocin Administration During Cesarean Section Phase 4
Not yet recruiting NCT02853552 - Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding Phase 4